A First-in-Human (FIH) Study of BG-C137, an Anti-Fibroblast Growth Factor Receptor 2b (FGFR2b) Antibody Drug Conjugate, in Participants With Advanced Solid Tumors
Recruiting · Phase 1 · NCT06625593
Conditions: Advanced Solid Tumor
At a glance
- Research payments reported, 2025
- $467,543
- U.S. investigators named
- 6
- Sites paid
- 7
- Planned or actual enrollment
- 168
About the trial
- Sponsor
- BeOne Medicines
- Tested
- BG-C137 (drug), Anticancer Agents (drug)
- Dates
- Started 2024-12-09; completion 2026-12-31
- Results posted
- Not yet
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BG-C137 alone and in combination with anticancer agents in participants with advanced solid tumors. The study will be conducted in two phases: Phase 1a (Monotherapy Dose Escalation, and Safety Expansion; Combination Dose Confirmation and Safety Expansion) and Phase 1b (Dose Expansion).
From ClinicalTrials.gov, last updated 2026-07-09. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Beone Medicines USA, Inc. reported $467,543 in research payments for this study in 2025 (34 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Mojun Zhu, M.D. Hematology & Oncology · Scottsdale, AZ
- Anthony B. El-khoueiry, M.D. Medical Oncology · Los Angeles, CA
- Michael Cecchini, MD Hematology & Oncology · New Haven, CT
- Nataliya V. Uboha, MD Hematology & Oncology · New Haven, CT
- Jordi Rodon, MD Medical Oncology · Houston, TX
- Andrew L. Coveler, MD Medical Oncology · Seattle, WA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- The Board of Regents of the University of Wisconsin System $128,547
- Ut MD Anderson Cancer Center $91,599
- Yale Cancer Center $68,813
- Mayo Clinic Scottsdale $61,418
- Fred Hutchinson Cancer Center $45,095
- University of Southern California, Norris Comprehensive Cancer Center $40,394
- Yale University $31,677
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.